

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

*\* listed in order of appearance*

## **Banks Bourne** | Founder & Chief Executive Officer | Bourne Partners

As Founder and CEO, Banks oversees all business operations and direct investment opportunities at Bourne Partners. He and the firm have been party to more than \$10 billion of transactions in the pharmaceutical (“pharma”), pharma services, and consumer healthcare sectors. Banks is also the founder of Tanner Pharma Group, a pharma services company dedicated to providing managed access, commercialization, and clinical trials services to patients and partners in more than 100 countries.

For almost 20 years, Bourne Partners has transacted with nearly all major pharmaceutical and specialty pharmaceuticals companies around the world, including Banks’ initial investment in King Pharmaceuticals in the late 1990’s. This investment introduced Banks to the pharmaceutical world and jump started his interest in the healthcare sector. Since then, he has invested in more than 200 private companies / assets.

While Banks has derived great satisfaction by offering focused advisory services to, and investing in, pharma, healthcare, and consumer-oriented companies that need strategic and operational insights, he is even more gratified knowing that his work has helped companies to improve the health and well-being of patients across the world. Banks is passionate about providing healthcare, and specifically pharmaceuticals, to less fortunate patients, as demonstrated by supporting The Max Foundation, Partners in Health, The Bourne Foundation, The Levine Children’s Hospital, and other non-profit organizations.

He received a B.A. degree in Business Management (Magna Cum Laude) from North Carolina State University and an M.B.A. from Wake Forest University. He is a member of Young Presidents Organization (YPO).

## **Somer Hamrick** | Founder & President | Channel Clinical Solutions

For the last two decades, Somer has served in business development roles in both public and private sectors across a variety of industries and multiple therapeutic areas. She has worked to establish industry partnerships to meet client needs for rapid start-up and other challenging environments, including projects supported by USAID, the U.S. Department of HHS and the Department of Defense. She co-developed and instituted training for clinical sites in five countries in Africa and Asia for the USAID-funded Site Identification and Development Initiative, and also co-facilitated and delivered stand-up training globally in topics including project management, team building, and off-site strategic planning.

In her most recent role as Vice President, Business Development, of FHI Clinical, formerly the Global Research Services (GRS) division of FHI 360, Somer influenced M&A activities to expand the company’s clinical research portfolio in the mid-size market. Additionally, she identified ways to maximize FHI 360’s public health impact and take advantage of its global presence through clinical trials support in low resource areas in Africa, Asia, and Latin America.

Prior to her role with FHI Clinical, Somer served as Director, Business Development at FHI 360. She successfully led a high-performance team to increase sales of clinical trial services through account development (pharmaceutical, biotech, US Government, and non-profit product development partners), pipeline management, proposal design, business intelligence and marketing. Somer formerly spent five years with FHI 360, serving as Business Development Manager and Strategic Partnerships Manager, where she established strong industry partnerships to meet client needs for rapid start-up in challenging environments.

Somer holds a bachelor’s degree in Communication from the University of North Carolina at Chapel Hill.

## **John Lagus** | Managing Director of Business Development | Tanner Pharma Group

John joined the Tanner team in 2019 and oversees the business development activities with a focus on Managed Access Programs. John began his career by applying his master’s degree in Statistics to clinical trials at The University of Minnesota and the pharmaceutical division of 3M Company. Then he spent 11 years at Orphan Medical, where he held various development, sales, marketing, and commercial roles, eventually overseeing their international business unit. Prior to joining Tanner Pharma, John worked for 12 years at Idis (and subsequently Clinigen after the merger of the two). While at Idis/Clinigen, John spent his entire time in their MAP Division performing Business Development and General Management roles of increasing responsibility.

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

## **Rob Keel** | Global Head of TannerMAP, Managing Director CH | Tanner Pharma Group

Rob oversees the Swiss Office while also leading the Managed Access Programs division. He has lived and worked extensively across the EMEA and Asia Pacific regions and has held global general management and finance roles within the pharmaceutical, airline and agriculture industries. Within the pharmaceutical industry, Rob has previously been responsible for the management and operation of the EMEA commercial supply chain at AstraZeneca and led business development activities at UK-based Alliance Healthcare. Rob holds an Industrial Engineering and Management Sciences degree from Northwestern University and an MBA from Harvard Business School.

## **Minor Hinson** | Senior Managing Director & Chief Investment Officer | Bourne Partners Strategic Capital

Since starting at Bourne Partners in 2011, Minor has been responsible for direct investment activities and has been very involved in both the Phoenix Therapeutics, Inc. joint venture with The Carlyle Group, as well as with the creation, management, and asset disposition of Covis Pharma S.à.r.l (“Covis”). Minor also served on the US Board of Covis from inception to exit and executed investments in AMRI, WellDyne, Novitium, iNova as well as various fund investments. Over the course of his career, Minor has been involved in over \$10 billion of financial transactions spanning the range of venture investing, private equity, mezzanine and senior debt, project finance debt and equity, cross boarder preferred stock issuances, sell-side and buy-side M&A transactions (both large cap and middle market), and other corporate finance advisory assignments.

Minor began his business career in 1984 in Corporate Banking at NCBN/NationsBank/Bank of America and became a Senior Relationship Manager in the Baltimore/Washington loan production office before deciding to attend business school in 1990. After an M.B.A. internship in corporate finance at The Coca Cola Company in Atlanta, Minor accepted a position as an Associate at Bowles Hollowell Conner & Company in Charlotte. Minor returned to Bank of America in 2002 to join the Strategic Investment Group, a function he eventually managed. He was then recruited to manage Corporate Development for the bank’s Global Treasury Services (\$4 billion in profit). In 2007, Minor decided to join Christofferson Robb & Company to raise capital and work on the initial London project team of the firm’s offshore wind farm (Thanet Offshore Wind Limited). Minor received a B.A. in Economics from Davidson College in 1984, as well as an M.B.A. (honor society) in 1992 from The Kenan-Flagler Business School at UNC Chapel Hill.

## **Kurt Orlofski** | Chief Executive Officer | Pharmaceutical Associates Inc. (PAI)

Kurt Orlofski, CPA, CMA, has served as CEO of Pharmaceutical Associates Inc. since Jan 2017. A leader and turnaround CEO, Kurt has led generic pharmaceutical companies for over 20 years. From 2009 to 2016, he was President and COO of G&W Laboratories. Prior to G&W, he was President of Wockhardt USA (Apr 2007 - Aug 2009). Prior to his time with Wockhardt, he was President and Chief Executive Officer of Pliva, the US subsidiary of global specialty pharmaceutical company Pliva. He was responsible for all Pliva US businesses including USD300m of generics business. Previously, Mr. Orlofski was Senior Vice President of Global Business Development at Alpharma Human Pharmaceuticals. His areas of expertise include pharmaceutical general management, transformational leadership, operations and quality management, sales and marketing in generics, new business unit start-ups, product acquisition, brand and generic in and out licensing of products and technology, business unit and asset sales and acquisitions (including integration), contract manufacturing deals in and out, and negotiation and execution of supplier and customer supply agreements.

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

## Andrew Callaway | U.S Head of Healthcare Investment Banking | RBC Capital Markets

Andrew Callaway is the U.S. Head of Healthcare Investment Banking at RBC Capital Markets. He oversees RBC's businesses in pharmaceuticals, biotechnology, medical technology, and healthcare services. Callaway joined RBC in March 2019 from Bank of America Merrill Lynch, where he was responsible for covering large-cap pharmaceutical and biotechnology companies. Prior to Bank of America Merrill Lynch, he was the Global Head of Life Sciences at Wells Fargo from 2016-2017 and Deutsche Bank from 2012-2016. Callaway has spent over 20 years in healthcare investment banking.

Callaway graduated from Amherst College with honors. He lives in New York with his wife and their three children.

## F. Alexander (Xan) Smith | Managing Director of Business Development | Bourne Partners

Xan is responsible for Bourne Partners' business development activities, with a focus on M&A, capital raising, licensing and partnering opportunities within the firm's pharmaceutical, pharma and healthcare services, and consumer health-focused investment banking advisory practice.

Xan Smith began his career in corporate banking at Wachovia Securities. Prior to Bourne Partners, he worked in investment banking at First Union Capital Markets where he was responsible for corporate finance solutions for select industry and Fortune 1000 clients. Most recently, he served as a Director of Scale Finance LLC where he provided capital and strategic advisory solutions for companies in high growth sectors. His professional experience also includes extensive involvement in real estate development, both with large scale master planned community developer, Crescent Resources, LLC/Morgan Stanley Real Estate, and as a principal of The Fulton Group LLC.

Xan received a B.A. in English with a minor in Business from Wake Forest University (cum laude) and spent an academic year abroad at The University of St. Andrews, Scotland, where he was a member of the University golf team. He also received an M.B.A. degree from Wake Forest University with a concentration in Finance.

## Tim Schroeder | Chief Executive Officer | CTI Clinical Trial and Consulting Services

Timothy Schroeder, CEO and Founder of CTI, has over 35 years of clinical, academic, and industry experience in global drug and device development programs. CTI, founded in 1999, is a multi-national research firm with associates in North America, Europe, Latin America and Asia-Pacific. The firm, which is one of the 20 largest CROs in the world and has supported more than 100 drug and device approvals, currently works on behalf of approximately 135 global pharmaceutical and biotechnology companies. Prior to founding CTI, Tim held numerous faculty positions with the University of Cincinnati College of Medicine. He was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, which went public in 1995. Tim is currently a board member for over a dozen corporate and non-profit organizations, including Xavier University, which he attended. Tim was named as an EY Entrepreneur of the Year in 2015, as Top Leader by the Enquirer Media in 2016, and as Deal Maker of the Year in 2017 by the Association for Corporate Growth.

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

## Jeff Ullman | Chief Executive Officer | GoodFOR

Jeff Ullman has extensive experience in the cannabis and CBD industries, and in 2015 created the YPO Cannabis Industry Wealth & Health Group.

Jeff has been a serial entrepreneur in numerous complex service industries ranging from singles and couples relationships to pharmacogenetic testing for Rx and cannabinoids, to creating and producing thousands of hours of original television programs. What kicked his commitment to CBD into high gear was his wife, Cindy, getting a prognosis of "death before Thanksgiving 2016" ... just six months from her Stage IV breast cancer diagnosis.

Jeff is now co-founder and CEO of GoodFOR.us, a creator of CBD-infused wellness, performance, and beauty products. In August of 2019, Jeff and Cindy released the first of dozens of CBD-centric OTC drugs: GoodFOR PAIN Level 6 and GoodFOR PAIN Level 8 (both topicals). Because the vast majority of people remain confused about what to expect from CBD, their focus is on brand identification as the most effective method to distinguish their company from others. Their solution is to position their brand by taking unrivaled advantage of everyday conversation: "What's good for my . . ."

## Bruce Montgomery | General Manager | Customer Marketing Group

Bruce is the General Manager of East Coast Operations for Customer Marketing Group (CMG). CMG is an analytics firm focused on helping consumer packaged goods (CPG) companies optimize their go-to market strategies with retailers. This includes optimizing trade spending, pricing, and distribution. Much of Bruce's career has been spent in the healthcare space, initially rising through the brand management ranks at Bayer Consumer Care and later running most commercial operations functions (sales, marketing, business development, new product development) at Fleet Laboratories over the course of 12 years.

Outside of work, Bruce is past Board Chair of Hospitality House of Charlotte, past member of Consumer Healthcare Products Association (CHPA) committees, co-founder of the Blue Ridge Lacrosse Club, co-founder of the Andrew Daniels Fish Stewardship Foundation (Muskoka Region, Ontario Canada), and is currently a fellow to the Mendoza College of Business at Notre Dame.

Bruce holds a B.A. degree in Economics from Denison University and an MBA in Marketing from the University of Notre Dame.

## Peter Caldini | Chief Executive Officer | Bespoke Capital Acquisition Corporation

Peter Caldini has over 25 years of experience in the consumer healthcare industry with multinationals Pfizer, Bayer, and Wyeth. He has extensive global commercial experience having led business operations across North America, EMEA, LATAM, and AsiaPac. He is currently the CEO of Bespoke Capital Acquisition Corporation, a special purpose acquisition corporation publicly traded on the TSX. Previously Peter was the Regional President of North America for Pfizer Consumer Healthcare (PCH). He was responsible for all the commercial operations for the US and Canada with over \$2 billion in revenue. Prior to the North America President role, Peter was the Regional President of EMEA for PCH. At Bayer, Peter held various roles with increasing responsibility. Most notably, Peter led the emerging markets cluster in EMEA (Turkey, Middle East, CIS, Maghreb, and all of Africa). He was also the Global Head of the Nutritionals Strategic Business Unit and the interim GM of China for Bayer. Peter holds a master's degree in International Economics and Management from SDA Bocconi in Milan, and an MBA from Northeastern University in Boston. He received his Bachelor of Arts in Political Science from Boston University. He also currently serves on the boards of Solvitrin Therapeutics, Kramer Labs, Premark Pharma, and is a senior advisor with Tuatara Capital.

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

## Roger Gravitte | Chief Operating Officer | The Emerson Group

Roger Gravitte has served as Chief Operating Officer for The Emerson Group since June 2015. Roger oversees The Emerson Group's marketing, logistics, business development, and consulting capabilities and operates out of their headquarters in Wayne, PA.

Prior to joining The Emerson Group, he served as General Manager Operating Unit Head in United Kingdom and Ireland for Novartis OTC and served as a member of the European leadership team. He was previously Head of Sales for Novartis OTC Americas.

Roger began his career with Wyeth Consumer Healthcare and ascended to sales leadership as Senior Vice President of Sales US. Roger is a member of several industry associations and has served on boards at NACDS and CHPA.

Roger earned his BA from University of Tennessee. He and his wife Barbara have two sons and reside in Wayne, Pennsylvania.

## Susan B. Levy | Founder & Principal | Susan B. Levy Consulting

Susan has over 30 years of global, cross-functional experience in the consumer healthcare industry and has worked across many therapeutic categories for industry leaders such as Merck/Schering-Plough, Pfizer/Warner-Lambert and SmithKline Beecham.

In 2011, Susan founded a boutique consulting firm providing strategy, business development, and marketing services in the consumer healthcare space. Susan B. Levy Consulting, LLC works with consumer healthcare companies to develop and implement growth strategies, including acquisitions/divestitures, technology search/licensing, Rx to OTC switch, geographic expansion initiatives, and effective and efficient marketing programs. Susan has been a featured presenter at multiple conferences. She has served on several for-profit and non-profit boards and is the recipient of multiple honors and awards.

Susan holds a B.A. in Chemistry from Cornell University and attended NYU Stern School of Business for her MBA.

## Dave Spence | Chairman | Legacy Pharmaceutical Packaging

David R. Spence currently serves as Chairman of Legacy Packaging, a contract pharmaceutical packager in Earth City, MO. David is also the Founder and former CEO of Alpha Packaging, a manufacturer of plastic bottles and jars. Alpha Packaging was sold in 2010.

A St. Louis native, David stays involved in his local community through organizations such as the Regional Business Council and the St. Louis Sports Commission. He is also involved in charitable organizations like the Order of Malta, a Catholic Worldwide Relief Organization. He is married to wife Suzie and together they have four children.

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

## George Zorich | Former Chief Executive Officer | Agilis Biotherapeutics

George Zorich has been in pharmaceutical fields for over 30 years, including big pharma, biotech, generics, distribution companies, and start-ups. Most recently, Mr. Zorich was CEO of Agilis Biotherapeutics, a company focused on developing a cure for Friedreich's ataxia using DNA based therapies. Prior to his time there, Mr. Zorich was president of Bioniche Pharmaceuticals, a manufacturer of branded and generic injectable products, leading to the sale to Mylan Pharmaceuticals for \$550MM in late 2010. He has also held executive positions with Sabex-USA, GIV, Fujisawa (now Astellas), Akorn Pharmaceuticals, Roxane Laboratories, and Eli Lilly and Company.

Mr. Zorich is committed to giving back to the community through organizations such as Reading Power, Brothers United, and ReNew North Chicago.

His award winning book *Entrepreneurs in Pharmacy and other Leaders* is available at Amazon books (paperback and e-book). All royalties go towards entrepreneurship programs.

Mr. Zorich received his pharmacy degree from the University of Wisconsin.

## Patrick Walsh | Chief Executive Officer | TriPharm Services

Patrick is an Operating Partner at Ampersand Capital, a private equity healthcare firm with Ampersand Capital Partners, and Co-Founder & CEO of TriPharm Services, a new 33,000 square foot parenteral fill finish manufacturing CMO based in Durham, North Carolina.

From 2015 to 2019, he served as the CEO of Avista Pharma Solutions in Durham, North Carolina. While at Avista, the rapid business growth resulted in a pre-emptive sale of the company to Cambrex Corp in January 2019 for \$252 million. Prior to his time with Avista, Mr. Walsh was the CEO of AAI Pharma Services in Wilmington, North Carolina, a private, equity-backed global provider of contract manufacturing and analytical testing services, where he led the sale of the company for a 4.6 times return. Mr. Walsh's earlier career includes serving as CEO of Kadmus Pharmaceuticals, Inc., in Irvine, California, and serving as president and chief operating officer of publicly-traded Gensia Sicor Pharmaceuticals, Inc.

Patrick currently serves as an independent director of the Board of Directors of Avid Bioservices (CDMO: Nasdaq), a publicly-traded company based in Tustin, California. He also serves as an independent director on the board of MedPharm, a private-equity backed contract development business, and an independent director at specialty pharma ANI Pharma (ANIP: Nasdaq).

In addition, prior board of director roles include serving as Chairman of Brammer Bio and numerous other pharma and biotechnology companies over the course of his 35-year career in the healthcare industry.

## Shawn Reilley | Chief Executive Officer | Aphenia Pharma Solutions, Inc.

Shawn Reilley has served as CEO of Aphenia Pharma Solutions since November of 2018. Shawn is a senior executive business leader with 26 years in the pharmaceutical, packaging, and plastics industries. Prior to his time with Aphenia, he built the fastest growing and most profitable Pharmaceutical Packaging Company in North America, driving sales from \$30 million to \$240 million per annum. He also launched 4 specialty business units (scheduled drugs, biologics, potent compounds, and clinical packaging) in 2009, all profitable. He led broad cost reduction initiative significantly overachieving all KPI's with \$24 million in annual cost out recognized, increasing EBITDA 180 basis points in 2017. He has successfully driven revenue, profits, and business growth from start-ups to acquisitions and from turnaround situations to high growth companies.

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

## Christopher Inklebarger | Chief Operating Officer & General Counsel | Bourne Partners

As Chief Operating Officer and General Counsel at Bourne Partners, Chris Inklebarger oversees the firm's operations and strategy execution. He also evaluates investment opportunities and works on select management consulting assignments. Chris heads up all of the firm's administrative and operational units, including legal, marketing, accounting, IT, and HR. Chris also serves as the Chief Compliance Officer and AMLCO for Bourne Partners Securities, the firm's registered broker dealer. He has held various positions and roles within Bourne Partners and its affiliated companies throughout his career with the firm, joining the team full-time after working as a summer associate during business school.

Chris received his B.S. from the University of Tennessee and earned a J.D. and an M.B.A. from the University of Tennessee College of Law and the Haslam College of Business. Prior to joining Bourne Partners, Chris worked with the Triple-A affiliate of the White Sox, the Charlotte Knights.

Chris actively supports the Beyond Limits Program at the Harris YMCA, Urban Promise, and the University of Tennessee.

## Artemis Emslie | Chief Executive Officer | Cadence Rx

With 25 years of experience in both workers' compensation and group health industries, Artemis Emslie brings a multi-dimensional perspective to the complex issues facing pharmacy benefit management (PBM) clients.

Artemis is the founder and CEO of Cadence Rx, a peer to peer pharmacy platform. Previously the CEO of myMatrixx, Artemis led the strategic growth of the company from a regional PBM to an industry leader with a national client base serving corporate and public sector groups of all sizes. After a successful sale to Express Scripts in May 2017, Artemis oversaw the successful year-long transition to the workers' compensation division of the nation's largest PBM. Prior to joining myMatrixx in 2012, Artemis held senior leadership positions with several companies before launching ProsperX Solutions, an auditing firm for workers' compensation insurance providers where she provided PBM claims auditing, RFP management, and consulting services to several blue-chip clients.

Artemis founded and currently serves on the executive board of the Alliance of Women in Workers' Compensation, a think tank committed to sharing ideas and mentoring tomorrow's industry leaders. Currently, she serves on the board of directors for Paradigm Outcomes, Ametros as well as on the advisory boards for AffordiT, Cordant Health, Committee for Economic Development (Washington, D.C.), Business Insurance magazine, Kids' Chance, and is the Chairperson of American Heart Association Circle of Red.

## Jeremy Johnson | Managing Director | Bourne Partners

Jeremy has 19 years of healthcare-focused M&A and private equity experience. He has been with Bourne Partners since 2006 and is part of the core leadership team at the firm. Jeremy currently serves as a Managing Director, overseeing the broker dealer and all Investment Banking activities. He also leads a transaction team that drives much of the firm's buy-side efforts for existing portfolio companies and new investment opportunities.

Prior to Bourne Partners, Jeremy was a founding member and Managing Director at Madison Keats, a life sciences strategy and consulting firm. Jeremy began his career at VentureWorx, an Internet incubator. He is a graduate of Georgetown University where he earned a bachelor of arts in Economics.

# GLOBAL HEALTHCARE EXECUTIVE SUMMIT

## Milton Boyer | Chief Executive Officer | SCA Pharmaceuticals, Inc.

Milton Boyer joined SCA Pharmaceuticals in September of 2017. Mr. Boyer has served in technical, commercial, and executive roles in the pharmaceutical industry for more than 25 years with a specific focus in contract manufacturing for both drug substance and sterile drug product. For the last 10+ years, he has been prominently involved in sterile drug product manufacturing, serving as Head of Drug Product Manufacturing at Albany Molecular Research Inc., and President and CEO of Oso BioPharmaceuticals.

Mr. Boyer serves on the board of directors of the Drug, Chemical & Associated Technologies Association (DCAT) and is now on the executive committee as its President. He has also served on the external advisory board for the University of New Mexico's chemistry and biology department and has been an active member of other professional organizations, including the American Association of Pharmaceutical Scientists, the Parenteral Drug Association, and the Society of Chemical Manufacturers and Affiliates. Mr. Boyer has a bachelor's degree in Chemistry/Physics from Hardin-Simmons University and a master's degree in Biochemistry from Texas Tech University.

## Robin Smith Hoke | Chief Executive Officer | Leiters

Ms. Robin Smith Hoke is the President & Chief Executive Officer of Leiters. Prior to joining Leiters, Ms. Hoke served as the Chair of the Board of Directors and Interim Chief Executive Officer at Ricerca Biosciences, a private equity backed pre-clinical CRO.

Robin also served as President and General Counsel for GeneraMedix, Inc., a generic and specialty pharmaceutical company serving the acute care market. Prior to GeneraMedix, she served in a variety of executive roles at Cardinal Health, including Senior Vice President of Global Business Development and Strategic Initiatives, Generic Pharmaceuticals, and General Counsel for Cardinal Health's Pharmaceutical Technologies & Services business. She has held legal roles at Abbott Laboratories and as a Partner in the business law firm of Kegler, Brown, Hill & Ritter, Co., L.P.A.

Ms. Hoke currently serves on the Board of Directors of Aeterna Zentaris, a bio-pharmaceutical company that serves the needs of patients with rare endocrine diseases, and as an Independent Director for Camargo Pharmaceuticals, LLC., a global 505B2 specialty company.

Robin received her law degree from Western Michigan School of Law and her B.S. from Michigan State University.

## Stuart Hinchin | Chief Executive Officer | QuVa Pharma, Inc.

Stuart Hinchin co-founded QuVa Pharma in 2015. Stuart has been an active leader in the pharmaceutical marketplace throughout his career. In 2007, he co-founded JHP Pharmaceuticals, LLC, and was instrumental in establishing it as a leading injectable pharmaceutical company in the United States before selling the business in 2014. He was CEO of JHP from 2011-2014, after serving as its President and COO from 2007-2011.

Previously, Stuart was President of Mayne Pharma Americas, a unit of Mayne that was focused on the manufacture, development, and sale of generic injectable pharmaceuticals, primarily into the hospital market. He led the Americas activity through a period of significant growth and established Mayne Pharma USA as a stand-alone business, ultimately building the division into one of the leading generic oncology providers in the United States.



# GLOBAL HEALTHCARE EXECUTIVE SUMMIT



## William Humphries

President

Ortho Dermatologics (Bausch Health Companies)

Bill Humphries joined Bausch Health Companies as President and Company Group Chairman for the Medical Dermatology and Global Solta businesses in December of 2016. He is a member of the Bausch Health Executive Team and the site lead for the Raleigh, NC office location. Over the past 3 years he has led the stabilization and turnaround of the legacy Valeant dermatology business through novel business model changes, talent retention and attraction, talent development, and the launch of 5 new products from the Bausch Health pipeline.

Bill has more than 32 years of experience in the specialty pharmaceutical industry, with more than 30 of those years focused on the commercialization of dermatology specialty pharmaceutical products.

In March 2012, Bill joined Merz, Inc. (affiliate of Merz Pharma Group), as President and Chief Executive Officer of its North American business. He was a member of the Merz Pharma Board and the Chairman of the Merz, Inc. Board of Directors. Bill successfully expanded the product portfolio, integrated the entire company, assisted on the acquisition and integration of 3 businesses, settled a product injunction, relocated the North American company headquarters, and ultimately doubled the revenue of the business delivering a \$156M profit turnaround for the company and shareholders over five years.

In August 2009, Bill was appointed President of Stiefel, a GSK company, after GlaxoSmithKline (GSK) successfully acquired Stiefel Laboratories in July 2009 for \$3.6 billion dollars. Bill was a key leader in this transaction and the commercial lead for the global integration of Stiefel into GSK.

From April 2008 to August 2009, Bill served as President of Stiefel Laboratories. Previously, Bill was Senior Vice President, US Commercial Operations and Chief Commercial Officer. Beginning in April 2006, he served as a member of the Company's Board of Directors. Bill was a key leader in two major acquisitions for Stiefel: Barrier Therapeutics, Inc., which completed in 2008, and Connetics Corporation, which completed in 2006. During his tenure at Stiefel, Bill spearheaded the development of the company's global commercial infrastructure, commercialization of its product portfolio, and managed worldwide operational initiatives.

From 1996 to 2004, Bill served in numerous executive roles in sales and marketing, business development, and international marketing for Allergan, Inc. He completed his tenure with Allergan, Inc. as Vice President US Skin Care, where he successfully led the Skin Care business back to profitable growth and was a key colleague in the launch of Botox Cosmetic to Dermatologists.

Bill served on the board of ZARS Pharma, a privately held specialty pharmaceutical company that was successfully acquired by Nuvo Research in 2011, the GlaxoSmithKline Portfolio Investment Board and GlaxoSmithKline Ophthalmology Board. He currently serves as the Chairman of the Board of Clearside Biomedical, is the Chair of the North Carolina State University Global Luxury Management Board, Women's Dermatologic Society Industry Advisory Board, is on the steering committee for Carolina Entrepreneurial Development, and serves on the Aclaris Therapeutics Board. Bill received a Master's degree in Business Administration from Pepperdine University in Malibu, California. He completed his undergraduate studies at Bucknell University in Lewisburg, Pennsylvania, earning a Bachelor of Arts degree.